Ovid Therapeutics, Inc.

Looking ahead to 2025, industry leaders shared their insights into the key trends and topics they expect to see. Click on topic headings to read executive predictions. The insights in this article hav

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Under the leadership of industry veteran CEO Jeremy Levin and chief operating officer Meg Alexander, Ovid Therapeutics is making strategic moves to address unmet needs in neurology. In November 2024,

Results from Recursion Pharmaceuticals, Inc. ’s Phase II SYCAMORE study of REC-994 in symptomatic cerebral cavernous malformation (CCM) drew uncertainty despite meeting the trial’s safety and tolerab